New study reveals a safer alternative for long-term hepatitis B treatment
Researchers have studied the effects of switching from long-term tenofovir disoproxil fumarate to the antiviral besifovir dipivoxil maleatein (BSV) in patients with chronic hepatitis B. Switching to BSV may improve patient kidney and bone health.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.